The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EORTC CLTF 2018 | Novel therapies on the horizon for cutaneous T-cell lymphoma
Speaking from the European Organisation for the Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Task Force (CLTF) 2018 Congress, held in St. Gallen, Switzerland, Rudolf Stadler, MD, PhD, of the University Medical Center Minden, Minden, Germany, discusses new therapy options for cutaneous T-cell lymphoma, including brentuximab vedotin and mogamulizumab. In addition, Prof. Stadler discusses promising targets for therapeutic antibodies.
